老年类风湿关节炎患者使用改善病情抗风湿药的情况。

Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.

作者信息

Ranganath Veena K, Furst Daniel E

机构信息

Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90025-1670, USA.

出版信息

Clin Geriatr Med. 2005 Aug;21(3):649-69, viii. doi: 10.1016/j.cger.2005.02.010.

DOI:10.1016/j.cger.2005.02.010

PMID:15911212

Abstract

During the 10-year period since the last review was done by Gardner and Furst, studies have furthered our knowledge of use of disease-modifying antirheumatic drugs (DMARDs) in the elderly rheumatoid arthritis (RA) patient. This article will briefly review the clinical pharmacology of human as they age, and detail the effects of aging on the specific pharmacokinetics and responses to commonly used DMARDs. There has been some progress in understanding the elderly RA patient, however, there is insufficient data for much confidence in DMARDs effects in the elderly.

摘要

自加德纳（Gardner）和弗斯特（Furst）上次进行综述以来的10年期间，各项研究增进了我们对老年类风湿关节炎（RA）患者使用改善病情抗风湿药（DMARDs）的了解。本文将简要回顾人体随着年龄增长的临床药理学，并详细阐述衰老对常用DMARDs的特定药代动力学及反应的影响。在了解老年RA患者方面已取得了一些进展，然而，关于DMARDs对老年人的影响，现有数据不足，难以让人有足够信心。